Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

22.31
-0.2700-1.20%
Post-market: 22.310.00000.00%19:23 EST
Volume:1.88M
Turnover:41.60M
Market Cap:2.82B
PE:62.29
High:22.50
Open:22.46
Low:21.71
Close:22.58
52wk High:30.48
52wk Low:16.10
Shares:126.53M
Float Shares:78.12M
Volume Ratio:0.81
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3581
EPS(LYR):-1.5970
ROE:14.10%
ROA:5.13%
PB:7.04
PE(LYR):-13.97

Loading ...

Stock Track | Apellis Pharmaceuticals Plummets 22.30% Despite Beating Q3 Earnings Estimates

Stock Track
·
Oct 30, 2025

Stock Track | Apellis Pharmaceuticals Plunges 10.15% Pre-market Despite Beating Q3 Estimates

Stock Track
·
Oct 30, 2025

Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q3 EPS $1.67, vs. FactSet Est of $1.60

MT Newswires Live
·
Oct 30, 2025

Apellis Pharmaceuticals Q3 Basic EPS USD 1.71

Reuters
·
Oct 30, 2025

Apellis Q3 revenue jumps to $459 mln with Sobi payment

Reuters
·
Oct 30, 2025

Apellis Pharmaceuticals Inc - Cash and Cash Equivalents of $479 Mln as of Sept 30, 2025

THOMSON REUTERS
·
Oct 30, 2025

Apellis Pharmaceuticals Q3 Operating Income USD 223.183 Million

THOMSON REUTERS
·
Oct 30, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 30, 2025

Apellis Pharmaceuticals CFO Timothy Eugene Sullivan Reports Disposal of Common Shares

Reuters
·
Oct 24, 2025

Apellis Pharmaceuticals (APLS): Assessing Valuation Following Wells Fargo’s Upgrade and Renewed Analyst Confidence

Simply Wall St.
·
Oct 21, 2025

Apellis Pharmaceuticals Inc : Piper Sandler Raises Target Price to $30 From $28

THOMSON REUTERS
·
Oct 20, 2025

Apellis price target raised to $29 from $26 at BofA

TIPRANKS
·
Oct 20, 2025

Apellis Reports EMPAVELI Outperforms Iptacopan in Reducing Proteinuria in C3G Patients

Reuters
·
Oct 20, 2025

Apellis Pharmaceuticals General Counsel David O. Watson Reports Sale of Common Shares

Reuters
·
Oct 18, 2025

Apellis Pharmaceuticals Inc. to Announce Third Quarter 2025 Financial Results

Reuters
·
Oct 16, 2025

Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight From Equalweight, Adjusts Price Target to $32 From $29

MT Newswires Live
·
Oct 15, 2025

Apellis Pharmaceuticals, Inc. : Wells Fargo Raises to Overweight From Equal Weight

THOMSON REUTERS
·
Oct 15, 2025

RBC Capital Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Oct 10, 2025

Apellis Pharmaceuticals Director Sinclair Dunlop Reports Disposal of Common Shares

Reuters
·
Oct 03, 2025

Director Dunlop A. Sinclair Reports Disposal of Apellis Pharmaceuticals Common Shares

Reuters
·
Sep 24, 2025